1811 related articles for article (PubMed ID: 31557056)
1. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
[TBL] [Abstract][Full Text] [Related]
2. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
Lopes RD; Heizer G; Aronson R; Vora AN; Massaro T; Mehran R; Goodman SG; Windecker S; Darius H; Li J; Averkov O; Bahit MC; Berwanger O; Budaj A; Hijazi Z; Parkhomenko A; Sinnaeve P; Storey RF; Thiele H; Vinereanu D; Granger CB; Alexander JH;
N Engl J Med; 2019 Apr; 380(16):1509-1524. PubMed ID: 30883055
[TBL] [Abstract][Full Text] [Related]
4. Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial.
Vora AN; Alexander JH; Wojdyla DM; Aronson R; Granger CB; Darius H; Windecker S; Mehran R; Averkov O; Budaj A; Kong DF; Kobalava Z; Mehta RH; Mirza Z; Guimaraes PO; Parkhomenko A; Quadros A; Thiele H; Goodman SG; Lopes RD
Circulation; 2019 Dec; 140(23):1960-1963. PubMed ID: 31553201
[No Abstract] [Full Text] [Related]
5. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Hijazi Z; Alexander JH; Li Z; Wojdyla DM; Mehran R; Granger CB; Parkhomenko A; Bahit MC; Windecker S; Aronson R; Berwanger O; Halvorsen S; de Waha-Thiele S; Sinnaeve P; Darius H; Storey RF; Lopes RD
Circulation; 2021 Mar; 143(12):1215-1223. PubMed ID: 33461308
[TBL] [Abstract][Full Text] [Related]
6. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.
Bahit MC; Vora AN; Li Z; Wojdyla DM; Thomas L; Goodman SG; Aronson R; Jordan JD; Kolls BJ; Dombrowski KE; Vinereanu D; Halvorsen S; Berwanger O; Windecker S; Mehran R; Granger CB; Alexander JH; Lopes RD
JAMA Cardiol; 2022 Jul; 7(7):682-689. PubMed ID: 35612866
[TBL] [Abstract][Full Text] [Related]
7. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.
Lopes RD; Vora AN; Liaw D; Granger CB; Darius H; Goodman SG; Mehran R; Windecker S; Alexander JH
Am Heart J; 2018 Jun; 200():17-23. PubMed ID: 29898844
[TBL] [Abstract][Full Text] [Related]
8. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.
Welsh RC; Dehghani P; Lopes R; Wojdyla DM; Aronson R; Granger CB; Windecker S; Vora AN; Vinereanu D; Halvorsen S; Parkhomenko A; Mehran R; Alexander JH; Goodman S
Open Heart; 2022 Feb; 9(1):. PubMed ID: 35172988
[TBL] [Abstract][Full Text] [Related]
9. [Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
Darius H
Dtsch Med Wochenschr; 2020 Jul; 145(14):978-986. PubMed ID: 32668469
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Oldgren J; Steg PG; Hohnloser SH; Lip GYH; Kimura T; Nordaby M; Brueckmann M; Kleine E; Ten Berg JM; Bhatt DL; Cannon CP
Eur Heart J; 2019 May; 40(19):1553-1562. PubMed ID: 30793734
[TBL] [Abstract][Full Text] [Related]
11. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials.
Potpara TS; Mujovic N; Proietti M; Dagres N; Hindricks G; Collet JP; Valgimigli M; Heidbuchel H; Lip GYH
Europace; 2020 Jan; 22(1):33-46. PubMed ID: 31603196
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention.
Harskamp RE; Fanaroff AC; Lopes RD; Wojdyla DM; Goodman SG; Thomas LE; Aronson R; Windecker S; Mehran R; Granger CB; Alexander JH
J Am Coll Cardiol; 2022 Feb; 79(5):417-427. PubMed ID: 35115097
[TBL] [Abstract][Full Text] [Related]
13. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
Vranckx P; Valgimigli M; Eckardt L; Tijssen J; Lewalter T; Gargiulo G; Batushkin V; Campo G; Lysak Z; Vakaliuk I; Milewski K; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Goette A
Lancet; 2019 Oct; 394(10206):1335-1343. PubMed ID: 31492505
[TBL] [Abstract][Full Text] [Related]
14. Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis.
Haller PM; Sulzgruber P; Kaufmann C; Geelhoed B; Tamargo J; Wassmann S; Schnabel RB; Westermann D; Huber K; Niessner A; Gremmel T
Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):226-236. PubMed ID: 31198930
[TBL] [Abstract][Full Text] [Related]
15. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Cannon CP; Bhatt DL; Oldgren J; Lip GYH; Ellis SG; Kimura T; Maeng M; Merkely B; Zeymer U; Gropper S; Nordaby M; Kleine E; Harper R; Manassie J; Januzzi JL; Ten Berg JM; Steg PG; Hohnloser SH;
N Engl J Med; 2017 Oct; 377(16):1513-1524. PubMed ID: 28844193
[TBL] [Abstract][Full Text] [Related]
16. The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
Triska J; Haddadin F; Madanat L; Jabri A; Daher M; Birnbaum Y; Jneid H
Cardiovasc Drugs Ther; 2024 Jun; 38(3):605-619. PubMed ID: 35829979
[TBL] [Abstract][Full Text] [Related]
17. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.
Cannon CP; Gropper S; Bhatt DL; Ellis SG; Kimura T; Lip GY; Steg PG; Ten Berg JM; Manassie J; Kreuzer J; Blatchford J; Massaro JM; Brueckmann M; Ferreiros Ripoll E; Oldgren J; Hohnloser SH;
Clin Cardiol; 2016 Oct; 39(10):555-564. PubMed ID: 27565018
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.
Rivolo S; Di Fusco M; Polanco C; Kang A; Dhanda D; Savone M; Skandamis A; Kongnakorn T; Soto J
PLoS One; 2021; 16(11):e0259251. PubMed ID: 34767564
[TBL] [Abstract][Full Text] [Related]
19. The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Fanaroff AC; Lopes RD
Prog Cardiovasc Dis; 2021; 69():11-17. PubMed ID: 34883097
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Choi HI; Ahn JM; Kang SH; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
JACC Cardiovasc Interv; 2017 Jun; 10(11):1075-1085. PubMed ID: 28527773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
